• CD47 targeting
  • CD28 targeting
  • How it works

Selective CD47 targeting

A bispecific antibody approach

Step 1 – Guided inhibition

Bispecific antibodies bind Tumor Associated Antigen (TAA) with high affinity and block CD47 upon co-engagement at the cell surface. CD47 expressed by TAA-negative healthy cells is not bound or inhibited.

Selective Cd47 Targeting 1

Created with Biorender

Selective Cd47 Targeting 1

Created with Biorender

Step 2 – Enhanced Antibody Dependent Cellular Phagocytosis (ADCP)

ADCP is induced by antibody Fc (human IgG1) binding to Fc receptors on phagocytes (macrophages or dendritic cells). Tumor cell phagocytosis is increased by the blockade of the CD47-SIRPa interaction, the «don’t eat me signal».

Selective Cd47 Targeting

Created with Biorender

Selective Cd47 Targeting

Created with Biorender

Step 3 – Activation of the adaptive immune response

Dendritic Cells and Macrophages process and cross-present tumor antigens to T lymphocytes leading to the induction anti-tumor immunity and potentially durable responses.

Interested by this approach for your own projects? Partner with us

All drawings have been created by BIORENDER

Back

CD47 targeting

Safe and selective blockade of CD47 on tumors

Cancer cells CD47 conveys a «don’t eat me signal» to better escape the immune system. A large body of evidence indicates that blocking the activity of CD47 with monoclonal antibodies restores killing of tumor cells.

One major difficulty is that CD47 is expressed on every cell of the human body.

To overcome this limitation, we have developed a unique bispecific antibody approach to selectively block CD47 on cancer cells, leaving normal cells unaffected.

Do you want to know more about selective CD47 targeting?
Interested by this approach for your own projects? Partner with us.

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn